Viewing Study NCT01118533


Ignite Creation Date: 2025-12-25 @ 2:55 AM
Ignite Modification Date: 2025-12-26 @ 1:35 AM
Study NCT ID: NCT01118533
Status: COMPLETED
Last Update Posted: 2016-06-10
First Post: 2010-03-29
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Impact of Blades Used for Scheduled Orotracheal Intubation on Postoperative Sore Throat
Sponsor: Assistance Publique - Hôpitaux de Paris
Organization:

Study Overview

Official Title: A Prospective, Multicenter, Randomized and Single Bind Trial. Influence of Laryngoscope Blade Material on Postoperative PHARYNGEAL AND LARYNGEAL Morbidity Following Scheduled OroTracheal Intubation
Status: COMPLETED
Status Verified Date: 2016-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MPLIT
Brief Summary: Orotracheal intubation following general anesthesia requires blades to be performed. The risk of patients contamination with infectious agents related to reusable metal blades leads to promote single-use blades. Some of these latter are plastic and this material may need more strength to lift the jaw and expose the larynx before orotracheal intubation. Sometimes, change of blade, from plastic to metal, during the procedure is necessary to increase the larynx exposure. This change of blade may increase the frequency of sore throat following orotracheal intubation.

Consequently, the study hypothesis is an increase of both sore throat intensity and frequency with the plastic blades compared with the metal blades.

The primary purpose of the present study is to compare the impact of these two types of blades, metal versus plastic, on sore throat intensity and frequency following scheduled orotracheal intubation for general anesthesia
Detailed Description: Trial design :

This will be a multicenter, prospective, randomized and single-blind controlled study

Material and Methods :

The obtaining of the Ethic Committee approval allows the enrolment of 712 patients scheduled for surgery performed under general anesthesia with orotracheal intubation. Adult patients, 18 to 70 years-old, with grade I-II of ASA (American Society of Anesthesiology) status will be enrolled after clear information and obtaining, at the anesthesia visit, of the non-opposition to be enrolled in the trial.

At the anesthesia visit, the anesthesiologist will explain the purpose and protocol to the patients and then will propose them to participate to the study. The decision to be enrolled will be known at the pre-anesthesia visit, one day before the surgery. Therefore, the patients will have a delay between the anesthesia and pre-anesthesia visits to make a decision. The non-opposition to participate to the trial will be clearly mentioned in the medical file.

A randomization list will be established by a statistician. Informed and non-opposed patients will be allocated both a randomization number and a plastic or metal blade in the operating theatre via the Clean Web software.

The evaluation and measure of the primary outcome will be made in a single-blind way. The patients will evaluate the sore throat intensity being unaware of the type of blade used for the orotracheal intubation. An independent research assistant in each centre will collect data evaluated in both the operating room during the orotracheal intubation procedure and the post-operative period.

The duration of tracheal intubation will be defined as the time elapsing from the mouth insertion of the blade to the passage of the tube throughout the vocal cords announced by the operator. The intra-tracheal position of the tube will be confirmed by three squared cycles of capnography.

Protocol :

Anesthesia and monitoring:

Patients will be premedicated by hydroxyzine 1 mg kg-1 the previous evening and one hour before the transfer to the operating room.

The randomization is performed in the operating room just before the anesthesia induction.

The monitoring will be standard with:

* An electrocardiogram (lookout of cardiac rhythm modifications)
* A pulse oxymetry to lookout arterial oxygen saturation
* A non-invasive blood pressure monitoring
* A capnograph to lookout carbon dioxide elimination in the expired gas and to confirm the intra-tracheal position of the tube
* A gas analyser to control the concentration of administered halogenated volatile agents
* A neuromuscular blockade monitor to lookout the depth of the neuromuscular blockade required to perform tracheal intubation in optimal conditions. The monitoring will consist of stimulating the facial nerve 1 cm near the external eyelid corner by a train of four electric charges (30 mA). The muscular responses will be evaluated on the corrugator Supercilia by counting the number of contractions.
* A bispectral index (BIS) or entropy to monitor the hypnosis depth. The expected values will be 40-60 and 25-35, respectively.
* A manometer to control the tracheal tube cuff pressure Before anesthesia induction, patients will breathe 100% oxygen till expired oxygen concentration reach 90%. Intravenous anesthesia will be then performed with propofol (1.5-2.5 mg kg -1) as hypnotic, sufentanil (0.2 mcg kg-1) and atracurium (0.5 mg kg-1) as muscle relaxant. Cis-atracurium or vecuronium as middle acting muscle relaxant or SUNCCYNILCHOLINE as short acting muscle relaxant will be authorized. According to the randomization, the blade used for orotracheal intubation will be metal or plastic. The metal blade is reusable and the plastic blade is disposable. When the BIS or the entropy will reach 40-60 and 25-35, respectively, with efficient face mask ventilation (good thoracic amplitude following by capnography cycles), no response to the TOF at the corrugator Supercilia, the laryngoscopy will be performed according to the orotracheal intubation algorithm. Tracheal tube sizes will be 7 mm for female and 7.5 for males. Tracheal tube cuff will be standard.

After tracheal intubation, the anesthesia will be maintained with inhaled halogenated gas or intravenously. Inhaled gas will be moistened. Postoperative analgesia will be anticipated in the operating room with paracetamol 1 g, ketoprofen 100 mg and nefopam if necessary. In the absence of contraindication, the three analgesics will be administered during laparotomies. Wound and abdominal holes for laparoscopy will be infiltrated with ropivacaine. At the end of the surgery, the tracheal tube will be withdrawn according to the standard procedure recommended by the French Anesthesiology Society. Mouth secretions will be suctioned delicately. In the PACU, analgesia will be continued with according to a protocol adapted to the type of surgery. Morphine will be administered if pain VAS reaches 4/10. Pharyngeal and laryngeal morbidity evaluation will begin at the discharge of the PACU and will last 48 hours. If signs persist more than 48 hours, an ENT examination will be performed to make a diagnostic.

Statistics :

Sample size: The literature reports a 30% incidence of postoperative sore throat with metal blades. The hypothesis is that this incidence could increase from 30% to 40% if plastic blades are used. Un sample size of 356 patients per group is required to detect this increase of 10% with a Chi2 test, a statistic power (1-beta) of 0.80 and alpha type I error probability of 0.05.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: